高危前列腺癌患者尝试保留神经根治性前列腺切除术后的肿瘤学结局与标准非保留神经手术相当:一项纵向长期倾向匹配单中心研究
该单中心研究纳入726例接受开放根治性前列腺切除术的高危前列腺癌患者,其中84%(n=609)行保留神经手术。经倾向评分逆概率加权匹配后,保留神经组与非保留神经组在切缘阳性率、术后放疗需求、复发风险及生存结局上均无显著差异。作者认为,在全面评估客观与主观标准的前提下,高危患者可尝试保留神经手术而不影响长期肿瘤学结局。
要点
- 高危前列腺癌患者中,保留神经根治性前列腺切除术组与非保留神经组的切缘阳性率无显著差异(47% vs 49%,P=0.64)。
- 保留神经手术未增加任何复发风险(HR 0.99,95%CI 0.73-1.34,P=0.09),两组生存结局无显著差异(HR 0.65,95%CI 0.39-1.08)。
- 作者认为,在全面评估客观(如T分期)和主观(如术中组织层面评估)标准的前提下,高危患者可尝试保留神经手术而不影响长期肿瘤学结局。
核心结论
- 在高危前列腺癌患者中,保留神经根治性前列腺切除术可尝试而不影响长期肿瘤学结局,前提是全面评估客观(如T分期)和主观(如术中组织层面评估)标准。
研究设计与样本
- 单中心纵向长期倾向匹配研究,纳入连续接受开放根治性前列腺切除术的高危前列腺癌患者,高危定义为术前前列腺特异性抗原>20 ng/mL和/或术后国际泌尿病理学会分级组4或5(即Gleason评分≥8)和/或≥pT3和/或pN1(评估切除标本及淋巴结标本)。
- 共纳入726例患者,其中84%(n=609)接受保留神经根治性前列腺切除术。
- 采用倾向评分及逆概率治疗加权匹配保留神经与非保留神经患者的基线特征,以时间-事件分析肿瘤学结局并计算风险比(HR)。
主要发现
- 保留神经组与非保留神经组的切缘阳性率无显著差异(47% vs 49%,P=0.64)。
- 保留神经组与非保留神经组术后放疗需求无显著差异(HR 0.78,95%CI 0.53-1.15)。
- 保留神经手术未影响任何复发风险(HR 0.99,95%CI 0.73-1.34,P=0.09)。
- 保留神经组与非保留神经组生存无显著差异(HR 0.65,95%CI 0.39-1.08)。
- 保留神经组与非保留神经组的肿瘤特异性生存(HR 0.56,95%CI 0.29-1.11)和无进展生存(HR 0.99,95%CI 0.73-1.34)均无显著差异。
关键数值与推荐
- 高危前列腺癌定义:术前前列腺特异性抗原>20 ng/mL和/或术后国际泌尿病理学会分级组4或5(即Gleason评分≥8)和/或≥pT3和/或pN1。
- 切缘阳性率:保留神经组47% vs 非保留神经组49%(P=0.64)。
- 术后放疗需求:HR 0.78(95%CI 0.53-1.15)。
- 任何复发风险:HR 0.99(95%CI 0.73-1.34,P=0.09)。
- 生存:HR 0.65(95%CI 0.39-1.08);肿瘤特异性生存HR 0.56(95%CI 0.29-1.11);无进展生存HR 0.99(95%CI 0.73-1.34)。
临床怎么用
- 作者认为,在高危前列腺癌患者中可尝试保留神经根治性前列腺切除术,而不影响长期肿瘤学结局,前提是全面评估客观(如T分期)和主观(如术中组织层面评估)标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the long-term safety of nerve-sparing radical prostatectomy (NSRP) in men with high-risk prostate cancer (PCa) by comparing survival outcomes, disease recurrence, the need for additional therapy, and perioperative outcomes of patients undergoing NSRP to those having non-NSRP. PATIENTS AND METHODS: We included consecutive patients at a single, academic centre who underwent open RP for high-risk PCa, defined as preoperative prostate-specific antigen level of > 20 ng/mL and/or postoperative International Society of Urological Pathology Grade Group 4 or 5 (i.e., Gleason score ≥ 8) and/or ≥pT3 and/or pN1 assessing the RP and lymph node specimen. We calculated a propensity score and used inverse probability of treatment weighting to match baseline characteristics of patients with high-risk PCa who underwent NSRP vs non-NSRP. We analysed oncological outcome as time-to-event and calculated hazard ratios (HRs). RESULTS: A total of 726 patients were included in this analysis of which 84% (n = 609) underwent NSRP. There was no evidence for the positive surgical margin rate being different between the NSRP and non-NSRP groups (47% vs 49%, P = 0.64). Likewise, there was no evidence for the need for postoperative radiotherapy being different in men who underwent NSRP from those who underwent non-NSRP (HR 0.78, 95% confidence interval [CI] 0.53-1.15). NSRP did not impact the risk of any recurrence (HR 0.99, 95% CI 0.73-1.34, P = 0.09) and there was no evidence for survival being different in men who underwent NSRP to those who underwent non-NSRP (HR 0.65, 95% CI 0.39-1.08). There was also no evidence for the cancer-specific survival (HR 0.56, 95% CI 0.29-1.11) or progression-free survival (HR 0.99, 95% CI 0.73-1.34) being different between the groups. CONCLUSION: In patients with high-risk PCa, NSRP can be attempted without compromising long-term oncological outcomes provided a comprehensive assessment of objective (e.g., T Stage) and subjective (e.g., intraoperative appraisal of tissue planes) criteria are conducted.
引用
- Furrer MA, Sathianathen N, Gahl B, et al. Oncological outcomes after attempted nerve-sparing radical prostatectomy (NSRP) in patients with high-risk prostate cancer are comparable to standard non-NSRP: a longitudinal long-term propensity-matched single-centre study. BJU Int. 2023. PMID: 37548822. doi:10.1111/bju.16126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。